<DOC>
	<DOCNO>NCT00329641</DOCNO>
	<brief_summary>This phase II trial study well sorafenib work give together carboplatin paclitaxel treat patient stage IV melanoma eye . Drugs use chemotherapy , carboplatin paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib may help carboplatin paclitaxel work well make tumor cell sensitive drug . Sorafenib may also stop growth melanoma block enzyme need tumor cell growth block blood flow tumor . Giving sorafenib together carboplatin paclitaxel may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib , Carboplatin , Paclitaxel Treating Patients With Stage IV Melanoma Eye</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate ( confirm unconfirmed , complete partial response ) patient stage IV uveal melanoma treat sorafenib , carboplatin , paclitaxel . SECONDARY OBJECTIVES : I . Determine overall progression-free survival patient treat regimen . II . Determine toxic effect regimen patient . III . Determine , preliminarily , relationship clinical outcome baseline microvessel density ( MVD ) tumor specimen , change vascular endothelial growth factor ( VEGF ) level plasma urine , change MVD , change VEGF receptor-2 phosphorylation tumor , and/or change ERK 1/2 phosphorylation stimulate lymphocytes tumor . OUTLINE : This non-randomized , open-label , multicenter study . Patients receive carboplatin IV paclitaxel IV day 1 oral sorafenib twice daily day 2-19 . Treatment repeat every 21 day 6 course . * After 6 course , patient continue receive oral sorafenib alone twice daily absence disease progression unacceptable toxicity . [ Note : *If sorafenib discontinue prior course 6 , patient may continue receive carboplatin paclitaxel 6 course ; carboplatin paclitaxel discontinue prior course 6 , patient may continue receive sorafenib alone twice daily day 1-21 course absence disease progression unacceptable toxicity . ] After completion study treatment , patient follow periodically 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Criteria : Histologically proven uveal melanoma Must document disease progression = &lt; 1 prior systemic treatment Measurable disease , define &gt; = 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan No tumor involve major vessel Zubrod performance status 01 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine = &lt; 2 time upper limit normal ( ULN ) Bilirubin = &lt; 2 time ULN SGOT SGPT = &lt; 2 time ULN ( 5 time ULN hepatic metastasis present ) INR range ( usually 2 3 ) No active bleeding No bleeding diathesis , active coagulopathy , pathological condition carry high risk bleed No condition ( e.g. , gastrointestinal tract disease ) affect ability take oral medication require IV alimentation Not pregnant nursing Fertile patient must use effective contraception No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree 5 year At least 28 day since prior systemic treatment disease comprise 1 following : single chemotherapy agent/regimen ; single immunotherapy agent/regimen ; single investigational treatment agent/regimen At least 21 day since prior major surgery No prior sorafenib agent target raf kinase vascular endothelial growth factor ( VEGF ) VEGF receptor No prior surgical procedure affect absorption No concurrent systemic corticosteroid therapy Topical and/or inhale steroid allow No concurrent cytochrome P450 enzymeinducing antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) , rifampin , Hypericum perforatum ( St. John 's wort ) No prophylactic granulocyte/platelet colonystimulating factor first course treatment Concurrent fulldose oral anticoagulant ( e.g. , warfarin ) allow provide follow criterion meet : inrange INR ; stable dose oral anticoagulant ; active bleeding high risk bleed Stage IV disease No known varices No uncontrolled hypertension systolic blood pressure ( BP ) &gt; 140 mm Hg diastolic BP &gt; 90 mm Hg No significant traumatic injury within past 21 day No active , uncontrolled peptic ulcer disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>